GlassScriptPhysician profile
Garima Agrawal
NPI 1558854935
$3,931.32
in general payments reported to CMS, 2019-2025
36 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $868 · 2021: $1,058 · 2022: $679 · 2023: $189 · 2024: $135 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $578.20 | 2019-2025 | Briviact, Nayzilam |
| Abbvie INC. | $481.16 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Biogen, INC. | $340.11 | 2019-2022 | |
| Amgen INC. | $232.23 | 2019-2021 | |
| Lilly USA, LLC | $228.06 | 2019-2023 | Amyvid |
| Emd Serono, INC. | $220.13 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $153.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $147.49 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $140.37 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.49 | 2022 | |
| Acadia Pharmaceuticals INC | $133.57 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $130.09 | 2020-2021 | |
| Pfizer INC. | $120.54 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $109.90 | 2019-2020 | |
| Allergan, INC. | $93.84 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $76.28 | 2021-2022 | |
| Lundbeck LLC | $68.91 | 2019-2021 | |
| Neurelis, INC. | $67.70 | 2022-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $52.72 | 2019-2021 | |
| Csl Behring | $46.60 | 2021-2022 | |
| Ge Healthcare | $42.89 | 2020-2025 | |
| Adamas Pharmaceuticals, INC. | $33.62 | 2021 | |
| Genzyme Corporation | $32.28 | 2020 | |
| Acorda Therapeutics, INC | $30.39 | 2019-2021 | |
| Mdd US Operations, LLC | $29.07 | 2020-2021 | |
| Livanova USA, INC. | $28.93 | 2019 | |
| Zyla Life Sciences, INC. | $25.68 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $22.93 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.97 | 2021 | |
| Sk Life Science, INC. | $18.94 | 2021 | |
| Neurocrine Biosciences, INC. | $17.31 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.06 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.61 | 2021 | |
| Kyowa Kirin, INC. | $13.91 | 2021 | |
| Avion Pharmaceuticals | $12.63 | 2022 | |
| Portola Pharmaceuticals, LLC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garima Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.